According to the Big Market Research, the global cardiac biomarker testing market generated $7,638 million in 2018, and is projected to reach $18,232 million by 2026, growing at a CAGR of 11.4% driven by ability of cardiac markers for accurate and rapid prediction of heart failure
PORTLAND, Oregon , July 9, 2019 /PRNewswire/ -- Cardiac biomarkers are protein-based traceable substances used as an indicator of biologic state as well as for diagnostic and prognostic purposes associated with heart. The prevention of cardiac diseases by monitoring heart conditions via cardiac biomarker testing is the profound approach for obtaining rapid results for immediate diagnosing and treatment. Cardiac biomarkers testing are used as risk stratification for various cardiovascular diseases (CVDs), which include myocardial infraction, congestive heart failure, acute coronary syndrome (ACS), and others. The cardiac biomarkers testing that are widely used as an integrated diagnostic approach for CVDs include CK-MB, troponin I and T, myoglobin, BNPs, IMA, and others. The global cardiac biomarkers testing market has witnessed a greater demand over the past five to six years.
Request a Sample Copy: https://www.bigmarketresearch.com/request-sample/3201243
The ability of cardiac markers for accurate and rapid prediction of heart failure after the onset of chest pain acts as a key factor that boosts the growth of the Global Cardiac biomarkers Testing Market. In addition, promising features such as high accuracy, quick outcomes, and economic pricing of cardiac point of care (POC) testing drive the market growth. To keep the momentum of cardiac marker tests, key manufacturers offer customized solutions, thus propelling the growth of the market. The commercial application of multi-menu options for cardiac testing using different combinations of cardiac biomarkers and target-oriented solutions serves as the key opportunity for market expansion. However, limited specificity in some cases and side effects such as skeletal muscle injury restrains the growth of the cardiac biomarkers testing market.
The global cardiac biomarker testing market is segmented based on type, application, location of testing, and region. By type, the market is fragmented into myocardial muscle creatine kinase (CK-MB), troponins (T and I), myoglobin, brain natriuretic peptide (BNPs) or NT-proBNP, ischemia modified albumin (IMA), and others. Depending on application, it is categorized into myocardial infarction, congestive heart failure, acute coronary syndrome, atherosclerosis, and others. By location of testing, it is bifurcated into point of care testing and laboratory testing. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Get Discount on this Report: https://www.bigmarketresearch.com/request-for-discount/3201243
The top major industry players have been profiled in this research report such as Roche Diagnostics, Abbott Laboratories, Siemens Healthcare, Becton, Dickinson and Company, Bio-Rad Laboratories, BioMerieux, PerkinElmer Inc., Tosoh Corporation, Danaher Corporation and Thermo Fisher Scientific.
The other players in the value chain include (profiles not included in the report) andox Laboratories, Johnson and Johnson, Olympus Corporation, BG Medicines, ACS Biomarker B.V. and Cavadis Biomedical.
1. Biomarker Technologies Market by Product, Technology, Next Generation Sequencing, Application and Indication: Global Opportunity Analysis And Industry Forecast, 2019–2026
The biomarker technologies market accounted for $21,594 million in 2018, and is expected to reach $58,508 million by 2026, registering a CAGR of 13.2% from 2019 to 2026. Rise in prevalence of various diseases such as autoimmune diseases, cancers, and infectious disease boosts the growth of this market. In addition, the rise in research related to drug discovery, increase in healthcare expenditure, and surge in use of personalized medicine are some other factors that contribute toward the growth of this market.
2. Cancer Biomarkers Market by Profiling Technology, Biomolecules, Cancer Type, Application - Global Opportunity Analysis And Industry Forecast, 2014-2022
The market size of the global cancer biomarkers market was valued at $6,521 million in 2015 and is estimated to grow at a CAGR of 13% over the forecast period to reach $15,737 million in 2022. Market growth is attributed to the increasing incidences of cancers such as lung cancer, breast cancer, and prostate cancer among others coupled with growing importance of biological and targeted drug therapies and technological advancements in the field of cancer treatment. However, unregulated government laws and reimbursement policies; as well as high cost of drug development and threat of failure are anticipated to have an adverse effect on the market growth.
Big Market Research has a range of research reports from various publishers across the world. Our database of reports of various market categories and sub-categories would help to find the exact report you may be looking for.
Mr. Abhishek Paliwal
Big Market Research
5933 NE Win Sivers Drive, #205, Portland,
OR 97220 United States
Toll Free: +1-800-910-6452
SOURCE Big Market Research